nach oben

Breast Cancer Research and Treatment

Erschienen in:

27.01.2022 | Clinical trial

Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression

verfasst von: Changchun Li, Ruiqing Li, Xingchi Hu, Guangjun Zhou, Guoqing Jiang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Breast cancer metastasis is the main cause of cancer-related death in women worldwide. Current therapies have remarkably improved the prognosis of breast cancer patients but still fail to manage metastatic breast cancer. Here, the present study was set to explore the role of microRNA (miR)-660 from tumor-associated macrophages (TAMs) in breast cancer, particularly in metastasis.

Materials and methods

We collected breast cancer tissues and isolated their polarized macrophages as well as extracellular vesicles (EVs), in which we measured the expression of miR-660, Kelch-like Protein 21 (KLHL21), and nuclear factor-κB (NF-κB) p65. Breast cancer cells were transfected with miR-660 mimic, miR-660 inhibitor, and sh-KLHL21 and then the cells were co-cultured with EVs or TAMs followed by detection of invasion and migration. Finally, mouse model of breast cancer was established to detect the effect of miR-660 or KLHL21 on metastasis by measuring the lymph node metastasis (LNM) foci in femur and lung.

Results

KLHL21 was poorly expressed, whereas miR-660 was highly expressed in breast cancer tissues and cells. Of note, low KLHL21 expression or high miR-660 expression was related to poor overall survival. EVs-contained miR-660 was identified to bind to KLHL21, reducing the binding between KLHL21 and inhibitor kappa B kinase β (IKKβ) to activate the NF-κB p65 signaling pathway. Interestingly, EV-loaded miR-660 from TAMs could be internalized by breast cancer cells. Moreover, silencing of KLHL21 increased the number of lung LNM foci in vivo, while EVs-contained miR-660 promoted cancerous cell invasion and migration.

Discussion

Taken altogether, our work shows that TAMs-EVs-shuttled miR-660 promotes breast cancer progression through KLHL21-mediated IKKβ/NF-κB p65 axis.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492CrossRefPubMed

Ponde NF, Zardavas D, Piccart M (2019) Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol 16(1):27–44. https://doi.org/10.1038/s41571-018-0089-9CrossRefPubMed

Harbeck N, Gnant M (2017) Breast cancer. Lancet 389(10074):1134–1150. https://doi.org/10.1016/S0140-6736(16)31891-8CrossRefPubMed

Penault-Llorca F, Radosevic-Robin N (2016) Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nat Rev Clin Oncol 13(8):487–503. https://doi.org/10.1038/nrclinonc.2016.1CrossRefPubMed

Lapenna A, De Palma M, Lewis CE (2018) Perivascular macrophages in health and disease. Nat Rev Immunol 18(11):689–702. https://doi.org/10.1038/s41577-018-0056-9CrossRefPubMed

Komohara Y, Fujiwara Y, Ohnishi K, Takeya M (2016) Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 99(Pt B):180–185. https://doi.org/10.1016/j.addr.2015.11.009CrossRefPubMed

Ngambenjawong C, Gustafson HH, Pun SH (2017) Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev 114:206–221. https://doi.org/10.1016/j.addr.2017.04.010CrossRefPubMedPubMedCentral

Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, Fidanza A, Lopez-Yrigoyen M, Millar MR, Urman A, Ai Z, Spellman PT, Hwang ES, Dixon JM, Wiechmann L, Coussens LM, Smith HO, Pollard JW (2019) Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 35(4):588–602. https://doi.org/10.1016/j.ccell.2019.02.009CrossRefPubMedPubMedCentral

Qiu SQ, Waaijer SJH, Zwager MC, de Vries EGE, van der Vegt B, Schroder CP (2018) Tumor-associated macrophages in breast cancer: innocent bystander or important player? Cancer Treat Rev 70:178–189. https://doi.org/10.1016/j.ctrv.2018.08.010CrossRefPubMed

10.

Chen C, Liu JM, Luo YP (2020) MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages. J Zhejiang Univ Sci B 21(1):12–28. https://doi.org/10.1631/jzus.B1900452CrossRefPubMedPubMedCentral

11.

Bleckmann A, Leha A, Artmann S, Menck K, Salinas-Riester G, Binder C, Pukrop T, Beissbarth T, Klemm F (2015) Integrated miRNA and mRNA profiling of tumor-educated macrophages identifies prognostic subgroups in estrogen receptor-positive breast cancer. Mol Oncol 9(1):155–166. https://doi.org/10.1016/j.molonc.2014.07.023CrossRefPubMed

12.

Cianciaruso C, Beltraminelli T, Duval F, Nassiri S, Hamelin R, Mozes A, Gallart-Ayala H, Ceada Torres G, Torchia B, Ries CH, Ivanisevic J, De Palma M (2019) Molecular profiling and functional analysis of macrophage-derived tumor extracellular vesicles. Cell Rep 27(10):3062–3080. https://doi.org/10.1016/j.celrep.2019.05.008CrossRefPubMedPubMedCentral

13.

Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ (2018) Extracellular vesicles in cancer—implications for future improvements in cancer care. Nat Rev Clin Oncol 15(10):617–638. https://doi.org/10.1038/s41571-018-0036-9CrossRefPubMed

14.

Xie F, Zhou X, Fang M, Li H, Su P, Tu Y, Zhang L, Zhou F (2019) Extracellular vesicles in cancer immune microenvironment and cancer immunotherapy. Adv Sci (Weinh) 6(24):1901779. https://doi.org/10.1002/advs.201901779CrossRef

15.

Mori MA, Ludwig RG, Garcia-Martin R, Brandao BB, Kahn CR (2019) Extracellular miRNAs: from biomarkers to mediators of physiology and disease. Cell Metab 30(4):656–673. https://doi.org/10.1016/j.cmet.2019.07.011CrossRefPubMedPubMedCentral

16.

Qi Y, Zha W, Zhang W (2019) Exosomal miR-660-5p promotes tumor growth and metastasis in non-small cell lung cancer. J BUON 24(2):599–607PubMed

17.

Zhou H, Tang G, Zhao M, Xie L, Xie Y, Zhang Z, He X (2020) circFBXL5 promotes breast cancer progression by sponging miR-660. J Cell Mol Med 24(1):356–361. https://doi.org/10.1111/jcmm.14737CrossRefPubMed

18.

Krishnan P, Ghosh S, Wang B, Li D, Narasimhan A, Berendt R, Graham K, Mackey JR, Kovalchuk O, Damaraju S (2015) Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics 16:735. https://doi.org/10.1186/s12864-015-1899-0CrossRefPubMedPubMedCentral

19.

National Research Counci (2011) Guide for the care and use of laboratory animals, 8th edn. The National Academies Press, Washington, DC. https://doi.org/10.17226/12910CrossRef

20.

Sarrion-Perdigones A, Chang L, Gonzalez Y, Gallego-Flores T, Young DW, Venken KJT (2019) Examining multiple cellular pathways at once using multiplex hextuple luciferase assaying. Nat Commun 10(1):5710. https://doi.org/10.1038/s41467-019-13651-yCrossRefPubMedPubMedCentral

21.

Shen Y, Ye YF, Ruan LW, Bao L, Wu MW, Zhou Y (2017) Inhibition of miR-660-5p expression suppresses tumor development and metastasis in human breast cancer. Genet Mol Res. https://doi.org/10.4238/gmr16019479CrossRefPubMed

22.

Chen J, Song W, Du Y, Li Z, Xuan Z, Zhao L, Chen J, Zhao Y, Tuo B, Zheng S, Song P (2018) Inhibition of KLHL21 prevents cholangiocarcinoma progression through regulating cell proliferation and motility, arresting cell cycle and reducing Erk activation. Biochem Biophys Res Commun 499(3):433–440. https://doi.org/10.1016/j.bbrc.2018.03.152CrossRefPubMed

23.

Mei ZZ, Chen XY, Hu SW, Wang N, Ou XL, Wang J, Luo HH, Liu J, Jiang Y (2016) Kelch-like protein 21 (KLHL21) targets IkappaB kinase-beta to regulate nuclear factor kappa-light chain enhancer of activated B cells (NF-kappaB) signaling negatively. J Biol Chem 291(35):18176–18189. https://doi.org/10.1074/jbc.M116.715854CrossRefPubMedPubMedCentral

24.

Yang M, Chen J, Su F, Yu B, Su F, Lin L, Liu Y, Huang JD, Song E (2011) Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer 10:117. https://doi.org/10.1186/1476-4598-10-117CrossRefPubMedPubMedCentral

25.

Frankenberger C, Rabe D, Bainer R, Sankarasharma D, Chada K, Krausz T, Gilad Y, Becker L, Rosner MR (2015) Metastasis suppressors regulate the tumor microenvironment by blocking recruitment of prometastatic tumor-associated macrophages. Cancer Res 75(19):4063–4073. https://doi.org/10.1158/0008-5472.CAN-14-3394CrossRefPubMedPubMedCentral

26.

Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA (2009) MicroRNAs–the micro steering wheel of tumour metastases. Nat Rev Cancer 9(4):293–302. https://doi.org/10.1038/nrc2619CrossRefPubMed

27.

Nashtahosseini Z, Aghamaali MR, Sadeghi F, Heydari N, Parsian H (2021) Circulating status of microRNAs 660–5p and 210–3p in breast cancer patients. J Gene Med 23(4):e3320. https://doi.org/10.1002/jgm.3320CrossRefPubMed

28.

Peng B, Li C, He L, Tian M, Li X (2020) miR-660-5p promotes breast cancer progression through down-regulating TET2 and activating PI3K/AKT/mTOR signaling. Braz J Med Biol Res 53(12):e9740. https://doi.org/10.1590/1414-431X20209740CrossRefPubMedPubMedCentral

29.

Riggi N, Aguet M, Stamenkovic I (2018) Cancer metastasis: a reappraisal of its underlying mechanisms and their relevance to treatment. Annu Rev Pathol 13:117–140. https://doi.org/10.1146/annurev-pathol-020117-044127CrossRefPubMed

30.

Dongre A, Weinberg RA (2019) New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20(2):69–84. https://doi.org/10.1038/s41580-018-0080-4CrossRefPubMed

31.

Pastushenko I, Blanpain C (2019) EMT transition states during tumor progression and metastasis. Trends Cell Biol 29(3):212–226. https://doi.org/10.1016/j.tcb.2018.12.001CrossRefPubMed

32.

Ashaie MA, Chowdhury EH (2016) Cadherins: the superfamily critically involved in breast cancer. Curr Pharm Des 22(5):616–638. https://doi.org/10.2174/138161282205160127095338CrossRefPubMed

33.

Padmanaban V, Krol I, Suhail Y, Szczerba BM, Aceto N, Bader JS, Ewald AJ (2019) E-cadherin is required for metastasis in multiple models of breast cancer. Nature 573(7774):439–444. https://doi.org/10.1038/s41586-019-1526-3CrossRefPubMedPubMedCentral

34.

Hsu CC, Huang SF, Wang JS, Chu WK, Nien JE, Chen WS, Chow SE (2016) Interplay of N-Cadherin and matrix metalloproteinase 9 enhances human nasopharyngeal carcinoma cell invasion. BMC Cancer 16(1):800. https://doi.org/10.1186/s12885-016-2846-4CrossRefPubMedPubMedCentral

35.

Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436(7047):123–127. https://doi.org/10.1038/nature03688CrossRefPubMedPubMedCentral

36.

Padala C, Tupurani MA, Puranam K, Gantala S, Shyamala N, Kondapalli MS, Gundapaneni KK, Mudigonda S, Galimudi RK, Kupsal K, Nanchari SR, Chavan U, Chinta SK, Mukta S, Satti V, Hanumanth SR (2017) Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer. PLoS ONE 12(9):e0184448. https://doi.org/10.1371/journal.pone.0184448CrossRefPubMedPubMedCentral

37.

Linde N, Casanova-Acebes M, Sosa MS, Mortha A, Rahman A, Farias E, Harper K, Tardio E, Reyes Torres I, Jones J, Condeelis J, Merad M, Aguirre-Ghiso JA (2018) Macrophages orchestrate breast cancer early dissemination and metastasis. Nat Commun 9(1):21. https://doi.org/10.1038/s41467-017-02481-5CrossRefPubMedPubMedCentral

38.

Su S, Liu Q, Chen J, Chen J, Chen F, He C, Huang D, Wu W, Lin L, Huang W, Zhang J, Cui X, Zheng F, Li H, Yao H, Su F, Song E (2014) A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 25(5):605–620. https://doi.org/10.1016/j.ccr.2014.03.021CrossRefPubMed

39.

Lin YW, Lee LM, Lee WJ, Chu CY, Tan P, Yang YC, Chen WY, Yang SF, Hsiao M, Chien MH (2016) Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-kappaB DNA-binding activity. J Pineal Res 60(3):277–290. https://doi.org/10.1111/jpi.12308CrossRefPubMed

40.

Fusella F, Secli L, Busso E, Krepelova A, Moiso E, Rocca S, Conti L, Annaratone L, Rubinetto C, Mello-Grand M, Singh V, Chiorino G, Silengo L, Altruda F, Turco E, Morotti A, Oliviero S, Castellano I, Cavallo F, Provero P, Tarone G, Brancaccio M (2017) The IKK/NF-kappaB signaling pathway requires Morgana to drive breast cancer metastasis. Nat Commun 8(1):1636. https://doi.org/10.1038/s41467-017-01829-1CrossRefPubMedPubMedCentral

41.

Dembinski HE, Wismer K, Vargas JD, Suryawanshi GW, Kern N, Kroon G, Dyson HJ, Hoffmann A, Komives EA (2017) Functional importance of stripping in NFkappaB signaling revealed by a stripping-impaired IkappaBalpha mutant. Proc Natl Acad Sci USA 114(8):1916–1921. https://doi.org/10.1073/pnas.1610192114CrossRefPubMedPubMedCentral

42.

Marino S, Bishop RT, Logan JG, Mollat P, Idris AI (2017) Pharmacological evidence for the bone-autonomous contribution of the NFkappaB/beta-catenin axis to breast cancer related osteolysis. Cancer Lett 410:180–190. https://doi.org/10.1016/j.canlet.2017.09.034CrossRefPubMed

43.

Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y (2013) Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 24(4):542–556. https://doi.org/10.1016/j.ccr.2013.09.008CrossRefPubMed

44.

Hirschfeld M, Rucker G, Weiss D, Berner K, Ritter A, Jager M, Erbes T (2020) Urinary exosomal MicroRNAs as potential non-invasive biomarkers in breast cancer detection. Mol Diagn Ther 24(2):215–232. https://doi.org/10.1007/s40291-020-00453-yCrossRefPubMed

45.

Munoz-Rodriguez JL, Vrba L, Futscher BW, Hu C, Komenaka IK, Meza-Montenegro MM, Gutierrez-Millan LE, Daneri-Navarro A, Thompson PA, Martinez ME (2015) Differentially expressed microRNAs in postpartum breast cancer in Hispanic women. PLoS ONE 10(4):e0124340. https://doi.org/10.1371/journal.pone.0124340CrossRefPubMedPubMedCentral

46.

Nassar FJ, Nasr R, Talhouk R (2017) MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther 172:34–49. https://doi.org/10.1016/j.pharmthera.2016.11.012CrossRefPubMed

Titel: Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression
verfasst von: Changchun Li
Ruiqing Li
Xingchi Hu
Guangjun Zhou
Guoqing Jiang
Publikationsdatum: 27.01.2022
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2022
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-021-06433-y

Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer

Clinical trial

Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer

Clinical trial

Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study

Epidemiology

Breast cancer treatment patterns by age and time since last pregnancy in the Carolina Breast Cancer Study Phase III

Epidemiology

Insulin resistance and the development of breast cancer in premenopausal women: the Kangbuk Samsung Health Study

Epidemiology

The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation

Clinical trial

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

15.01.2025
Melanom
Nachrichten

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression